{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:16:20Z","timestamp":1785402980611,"version":"3.56.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Intravesical bacillus Calmette-Guerin (BCG) therapy is the treatment of choice for patients with T1 or high-grade superficial bladder cancer or those with carcinoma in situ after transurethral resection. A personal history of tuberculosis infection has been viewed as a relative contraindication for BCG therapy, because it may increase the risk of complications or decrease the treatment effectiveness. We determined the safety and efficacy of intravesical BCG treatment for patients with prior tuberculosis infection by analyzing the data obtained from the National Health Insurance Research Database in Taiwan.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We included patients who were newly diagnosed with bladder cancer from 2000 to 2009 and who received adjuvant intravesical BCG therapy within 3\u2009months after the surgery. We excluded those who developed upper urinary tract cancer during the study period. Disease recurrence, disease progression, and major adverse effects were compared between patients with and without a prior diagnosis of tuberculosis infection until December 31, 2011.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Among the 3915 patients included, 187 (4.8%) had been previously diagnosed with tuberculosis infection. The proportion of men (84.0% versus 76.9%) and older patients was higher in the group with a prior tuberculosis infection than in those without a prior tuberculosis infection. Significant differences in disease recurrence (20.3% versus 22.8%; hazard ratio [HR], 0.87; 95% confidence interval [CI], 0.63\u20131.21, <jats:italic>p<\/jats:italic>\u2009=\u20090.404) or disease progression (10.2% versus 12.8%, HR, 0.74; 95% CI, 0.46\u20131.17, <jats:italic>p<\/jats:italic>\u2009=\u20090.191) were not observed between the two groups. None of the patients with a prior tuberculosis infection had severe urinary tract infections, whereas four (0.1%) patients without such an infection developed severe urinary tract infections.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>A prior tuberculosis infection did not affect the treatment efficacy or safety of intravesical BCG treatment. The efficacy and safety of intravesical BCG therapy are comparable between bladder cancer patients with and without prior tuberculosis infections.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12894-020-00642-1","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T12:03:48Z","timestamp":1594209828000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Can we treat bladder cancer with intravesical Bacillus Calmette-Guerin in patients with prior tuberculosis infection? A population-based cohort study"],"prefix":"10.1186","volume":"20","author":[{"given":"Che-Wei","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chun","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiao-Yun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hua","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Chi","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ming","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,8]]},"reference":[{"key":"642_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"642_CR2","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","volume":"388","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Hahn NM, Efsttathiou JA, Lerner SP, Malmstr\u00f6m PU, Choi W, et al. Bladder cancer. Lancet. 2016;388:2796\u2013810.","journal-title":"Lancet."},{"key":"642_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, et al. EAU guidelines on non\u2013muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71:447\u201361.","journal-title":"Eur Urol"},{"key":"642_CR4","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.6004\/jnccn.2016.0131","volume":"14","author":"PE Clark","year":"2016","unstructured":"Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, et al. NCCN guidelines insights: bladder cancer, version 2.2016. J Natl Compr Cancer Netw. 2016;14:1213\u201324.","journal-title":"J Natl Compr Cancer Netw"},{"key":"642_CR5","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","volume":"116","author":"A Morales","year":"1976","unstructured":"Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116:180\u20133.","journal-title":"J Urol"},{"key":"642_CR6","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1007\/s11095-008-9566-7","volume":"25","author":"Z Shen","year":"2008","unstructured":"Shen Z, Shen T, Wientjes MG, O\u2019Donnell MA, Au JLS. Intravesical treatments of bladder cancer: review. Pharm Res. 2008;25:1500\u201310.","journal-title":"Pharm Res"},{"key":"642_CR7","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","volume":"178","author":"MC Hall","year":"2007","unstructured":"Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages ta, T1, and tis): 2007 update. J Urol. 2007;178:2314\u201330.","journal-title":"J Urol"},{"key":"642_CR8","doi-asserted-by":"crossref","unstructured":"van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV, EORTC Genito-Urinary Tract Cancer Group. Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol. 2003;44:429\u201334.","DOI":"10.1016\/S0302-2838(03)00357-9"},{"key":"642_CR9","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11192-010-0289-2","volume":"86","author":"Y-C Chen","year":"2011","unstructured":"Chen Y-C, Yeh H-Y, Wu J-C, Haschler I, Chen T-J, Wetter T. Taiwan\u2019s National Health Insurance Research Database: administrative health care database as study object in bibliometrics. Scientometrics. 2011;86:365\u201380.","journal-title":"Scientometrics."},{"key":"642_CR10","unstructured":"World Health Organization. Global tuberculosis report 2018. https:\/\/reliefweb.int\/sites\/reliefweb.int\/files\/resources\/9789241565646-eng.pdf. Accessed 23 Dec 2019."},{"key":"642_CR11","unstructured":"World Health Organization. WHO report 2009: global tuberculosis control\u2013epidemiology, strategy, financing https:\/\/reliefweb.int\/report\/world\/global-tuberculosis-control-2009-epidemiology-strategy-financing Accessed 23 Dec 2019."},{"key":"642_CR12","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/00005392-199707000-00017","volume":"158","author":"MS Cookson","year":"1997","unstructured":"Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol. 1997;158:62\u20137.","journal-title":"J Urol"},{"key":"642_CR13","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1097\/01.ju.0000073852.24341.4a","volume":"170","author":"A Bohle","year":"2003","unstructured":"Bohle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol. 2003;170:964\u20139.","journal-title":"J Urol"},{"key":"642_CR14","doi-asserted-by":"publisher","unstructured":"Biot C, Rentsch CA, Gsponer JR, Birkh\u00e4user FD, Jusforgues-Saklani H, Lema\u00eetre F, et al. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci Transl Med. 2012;4:137ra72. https:\/\/doi.org\/10.1126\/scitranslmed.3003586.","DOI":"10.1126\/scitranslmed.3003586"},{"key":"642_CR15","doi-asserted-by":"crossref","unstructured":"Niwa N, Kikuchi E, Matsumoto K, Kosaka T, Mizuno R, Oya M. Purified protein derivative skin test reactions are associated with clinical outcomes of patients with nonmuscle invasive bladder cancer treated with induction bacillus Calmette-Gu\u00e9rin therapy. Urol Oncol. 2018;36:e15\u201377.e21.","DOI":"10.1016\/j.urolonc.2017.10.005"},{"key":"642_CR16","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","volume":"89","author":"JA Mart\u00ednez-Pineiro","year":"2002","unstructured":"Mart\u00ednez-Pineiro JA, Flores N, Isoma S, Solsona E, Sebasti\u00e1n JL, Pertusa C, et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Gu\u00e9rin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int. 2002;89:671\u201380.","journal-title":"BJU Int"},{"key":"642_CR17","unstructured":"Chiou MY, Hsu BH, Huang YF, Chang HC. Assessment and perspective of BCG-vaccination policy in Taiwan. https:\/\/www.cdc.gov.tw\/En\/EpidemicTheme\/Detail\/hQ4XhaZAzUmNe2ksY4tjMA?archiveId=IDW4eMbqTQN1DaU4o8IaPg Accessed 03 Jun 2020."},{"key":"642_CR18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0022-5347(17)46972-2","volume":"134","author":"DL Lamm","year":"1985","unstructured":"Lamm DL. Bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol. 1985;134:40\u20137.","journal-title":"J Urol"},{"key":"642_CR19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0090-4295(85)90525-4","volume":"25","author":"HW Herr","year":"1985","unstructured":"Herr HW, Pinsky CM, Whitmore WF Jr, Sogani PG, Oettgen HF, Melamed MR. Experience with intravesical bacillus Calmette-Guerin therapy of superficial bladder tumors. Urology. 1985;25:119\u201323.","journal-title":"Urology."},{"key":"642_CR20","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0022-5347(17)43644-5","volume":"138","author":"HW Herr","year":"1987","unstructured":"Herr HW, Laudone VP, Whitmore WF Jr. An overview of intravesical therapy for superficial bladder tumors. J Urol. 1987;138:1363\u20138.","journal-title":"J Urol"},{"key":"642_CR21","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1086\/314064","volume":"31","author":"DL Lamm","year":"2000","unstructured":"Lamm DL. Efficacy and safety of bacille Calmette-Guerin immunotherapy in superficial bladder cancer. Clin Infect Dis. 2000;31:S86\u201390.","journal-title":"Clin Infect Dis"},{"key":"642_CR22","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1159\/000492722","volume":"101","author":"W Krajewski","year":"2018","unstructured":"Krajewski W, Matuszewski M, Poletajew S, Grzegrzolka J, Zdrojowy R, Kolodziej A. Are there differences in toxicity and efficacy between various bacillus Calmette-Gu\u00e9rin strains in bladder cancer patients? Analysis of 844 patients. Urol Int. 2018;101:277\u201384.","journal-title":"Urol Int"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-020-00642-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-020-00642-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-020-00642-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T23:18:54Z","timestamp":1625699934000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-020-00642-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,8]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["642"],"URL":"https:\/\/doi.org\/10.1186\/s12894-020-00642-1","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,8]]},"assertion":[{"value":"25 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We conducted this study in accordance with the guidelines stipulated in the Helsinki Declaration. This study protocol is compliant with ethical standards and approved by the local ethics committee (Taipei City Hospital). The NHIRD encrypts personal information of the patients to protect their privacy and provides researchers with anonymous identification numbers associated with the relevant claim information. The need for patient consent was waived because of the total anonymity of all research data in this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"91"}}